The use of melatoninergic antidepressants for stabilization of remission in depression comorbid with alcohol abuse, anxiety or neuropsychiatric disorders: a systematic review DOI Creative Commons
S. G. Klimanova, D. S. Radionov, N. I. Shova

и другие.

Consortium Psychiatricum, Год журнала: 2024, Номер 5(4), С. 40 - 62

Опубликована: Дек. 24, 2024

Depression is one of the most common mental disorders and associated with a significant increase in risk somatic comorbidities. The chronobiological theory pathogenesis depression explains relationship between symptoms disturbance circadian rhythm regulation. Disrupted rhythms are also observed other such as alcohol use disorder, anxiety disorders, epilepsy, Parkinson's disease. Therefore, there growing interest medications melatoninergic mechanism action treatment comorbid aforementioned disorders. This review aims to systematically examine evidence for antidepressants (agomelatine fluvoxamine) abuse, (including phobic anxiety, panic, generalized disorders), or neuropsychiatric (such epilepsy disease). systematic included experimental studies, reviews, meta-analyses published English Russian, which examined fluvoxamine agomelatine adult patients recurrent depressive disorder (ICD-10) major (DSM-5) search was conducted PubMed, Cochrane Library eLIBRARY scientific databases. quality selected studies assessed using Risk Bias tool, used evaluate errors clinical studies. results were presented narrative synthesis grouped by comorbidities evaluated. A total 20 articles reviewed (with pooled sample size n=1,833 participants). suggest that might help reducing symptoms, improve sleep, decrease cravings, alleviate severity motor Moreover, pharmacogenetic testing select medication dosage may enhance its therapeutic effectiveness. demonstrates lack data guidelines on In this regard, it currently difficult draw definitive conclusion regarding efficacy safety these Available an improvement manifestations Future research directions include development implementation double-blind, randomized trials study

Язык: Английский

Non-Pharmacological Interventions for Depression and Anxiety in Parkinson’s Disease DOI
Erwin E. H. van Wegen, Tim D. van Balkom, Mark A. Hirsch

и другие.

Journal of Parkinson s Disease, Год журнала: 2024, Номер 14(s1), С. S135 - S146

Опубликована: Апрель 9, 2024

Non-pharmacological interventions, including cognitive-behavioral therapy (CBT), non-invasive brain stimulation (NIBS), electroconvulsive (ECT), light (LT), and physical rehabilitation/exercise, have shown promise as effective approaches to treat symptoms of depression anxiety in individuals with Parkinson's disease (PD). In this narrative literature overview, we discuss the state-of-the-art regarding these treatment options address future perspectives for clinical practice research. interventions hold PD. There is meta-analytic evidence efficacy CBT, NIBS, ECT, LT, exercise on improving depressive symptoms. For symptoms, CBT shows large effects but scientific other non-pharmacological limited. Importantly, treatments are safe no or mild side-effects. More research needed tailor individuals' needs combined may provide synergistic effects.We conclude that should be considered alternative augmentative pharmacological neurosurgical

Язык: Английский

Процитировано

5
Blunted Melatonin Circadian Rhythm in Parkinson’s Disease: Express Bewilderment DOI
Areej Turkistani, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb

и другие.

Neurotoxicity Research, Год журнала: 2024, Номер 42(5)

Опубликована: Авг. 23, 2024

Язык: Английский

Процитировано

4
Prevalence and associations of self‐reported sleep problems in a large sample of patients with Parkinson's disease DOI Creative Commons
Ziba Asadpoordezaki, Beverley M. Henley, Andrew N. Coogan

и другие.

Journal of Sleep Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 19, 2025

Summary Sleep problems are important comorbid features of, and risk factors for, neurodegenerative diseases such as Parkinson's disease (PD). To assess the prevalence associations of sleep in patients with PD we analysed data from almost 54,000 participants Fox Insight study, including 38,588 PD. common PD, ~84% respondents reporting difficulty falling or staying asleep. Experiences insomnia, restless leg syndrome, vivid dreams, acting out use medication over‐represented compared matched healthy controls. Male sex onset before age 50 were also associated a greater problems. A physician diagnosis insomnia was more symptoms depression, impairment cognition‐dependent independence, lower quality life. higher OFF periods without 6.7% endorsed complaints their most bothersome symptom, reported non‐specific poor problem. These had better life depression cognitive impairments than for whom postural instability indicating relative burden is contextualised by severity motor symptoms. Overall, these findings reinforce high very large sample patients, indicate daily function

Язык: Английский

Процитировано

0
Chronobiology of Parkinson's disease: Past, present and future DOI
Ziba Asadpoordezaki, Andrew N. Coogan, Beverley M. Henley

и другие.

European Journal of Neuroscience, Год журнала: 2022, Номер 57(1), С. 178 - 200

Опубликована: Ноя. 7, 2022

Parkinson's disease is a neurodegenerative disorder predominately affecting midbrain dopaminergic neurons that results in broad range of motor and non-motor symptoms. Sleep complaints are among the most common symptoms, even prodromal period. alterations patients may be associated with dysregulation circadian rhythms, intrinsic 24-h cycles control essential physiological functions, or side effects from levodopa medication physical mental health challenges. The impact on sleep disturbances not fully understood; as such, we review systems, cellular molecular mechanisms underlie perturbations disease. We also discuss potential benefits chronobiology-based personalized medicine management both terms behavioural pharmacological interventions. propose fuller understanding clock function shed important new light aetiology symptomatology allow for improvements quality life millions people

Язык: Английский

Процитировано

16
Molecular Links Between Circadian Rhythm Disruption, Melatonin, and Neurodegenerative Diseases: An Updated Review DOI Creative Commons
K. Hüsnü Can Başer, Ismail Celil Haskologlu, Emine Erdag

и другие.

Molecules, Год журнала: 2025, Номер 30(9), С. 1888 - 1888

Опубликована: Апрель 23, 2025

Circadian rhythms are molecular oscillations governed by transcriptional–translational feedback loops (TTFLs) operating in nearly all cell types and fundamental to physiological homeostasis. Key circadian regulators, such as locomotor output cycles kaput (CLOCK), brain muscle ARNT-like 1 (BMAL1), period (PER), cryptochrome (CRY) gene families, regulate intracellular metabolism, oxidative balance, mitochondrial function, synaptic plasticity. disruption is known a central contributor the pathophysiology of neurodegenerative disorders. Disease-specific disruptions clock expression melatoninergic signaling potential early-stage biomarkers. Melatonin, neurohormone secreted pineal gland, modulates expression, stability, inflammatory responses. It also regulates epigenetic metabolic processes through nuclear receptors regulators involved cellular stress pathways, thereby exerting neuroprotective effects maintaining neuronal integrity. This review provides recent findings from past five years, highlighting how dysregulation mediates key disturbances translational circadian-based therapies diseases.

Язык: Английский

Процитировано

0
Neurologic music therapy for inhibitory control in parkinson’s disease: Intervention protocol for a feasibility study DOI
Leonardo Francisco Citon, Amer Cavalheiro Hamdan

Applied Neuropsychology Adult, Год журнала: 2025, Номер unknown, С. 1 - 8

Опубликована: Май 16, 2025

Introduction: Impairments in inhibitory control are common and directly impact the quality of life individuals with Parkinson's Disease (PD). Non-pharmacological interventions for this population primarily focus on motor outcomes, cognitive aspects often overlooked. Neurologic Music Therapy (NMT), a model integrating neuroscience music therapy techniques, may have significant potential rehabilitation. This study aims to evaluate feasibility home-based NMT intervention, focusing primary outcomes related intervention's secondary concerning cognition PD. Method: Five (n = 5) diagnosed PD will be recruited. Participants receive three 30-minute sessions per week over four weeks. Pre- post-intervention assessments conducted. The assessment protocol include questionnaires (sociodemographic/clinical therapy); tests inclusion criteria; through recruitment rate, retention dropout acceptability, researcher report; evaluation clinical Stroop Color-Word Test, Hayling Go/No-Go Task, Questionnaire-39 (PDQ-39), Unified Rating Scale (MDS/UPDRS). Discussion: provide essential insights planning conducting larger trial, offering important data recruitment, evaluation, intervention design, musical techniques control.

Язык: Английский

Процитировано

0
Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder DOI Creative Commons

Daniel P. Cardinali,

A. Garay

Brain Sciences, Год журнала: 2023, Номер 13(5), С. 797 - 797

Опубликована: Май 13, 2023

Dream-enactment behavior that emerges during episodes of rapid eye movement (REM) sleep without muscle atonia is a parasomnia known as REM disorder (RBD). RBD constitutes prodromal marker α-synucleinopathies and serves one the best biomarkers available to predict diseases such Parkinson disease, multiple system atrophy dementia with Lewy bodies. Most patients showing will convert an α-synucleinopathy about 10 years after diagnosis. The diagnostic advantage relies on prolonged time, its predictive power absence disease-related treatments could act confounders. Therefore, are candidates for neuroprotection trials delay or prevent conversion pathology abnormal α-synuclein metabolism. administration melatonin in doses exhibiting chronobiotic/hypnotic effect (less than mg daily) commonly used first line treatment (together clonazepam) RBD. At higher dose, may also be effective cytoprotector halt progression. However, allometric derived from animal studies (in 100 mg/day range) rarely employed clinically regardless demonstrated toxicity phase 1 pharmacological up normal volunteers. This review discusses application RBD: (a) symptomatic RBD; (b) possible disease-modifying α-synucleinopathies. To what degree has therapeutic efficacy prevention awaits further investigation, particular multicenter double-blind trials.

Язык: Английский

Процитировано

7
Zustandsschwankungen bei der Parkinson-Krankheit jenseits von On‑/Off-Fluktuationen DOI
Georg Ebersbach, Günter U. Höglinger, Thomas Koeglsperger

и другие.

DGNeurologie, Год журнала: 2024, Номер 7(6), С. 453 - 460

Опубликована: Окт. 8, 2024

Процитировано

2
Fighting Against the Clock: Circadian Disruption and Parkinson’s Disease DOI Creative Commons

Yen-Chung Chen,

Wei-Sheng Wang, Simon J.G. Lewis

и другие.

Journal of Movement Disorders, Год журнала: 2023, Номер 17(1), С. 1 - 14

Опубликована: Ноя. 21, 2023

Circadian disruption is being increasingly recognized as a critical factor in the development and progression of Parkinson’s disease (PD). This review aims to provide an in-depth overview relationship between circadian PD by exploring molecular, cellular, behavioral aspects this interaction. will include comprehensive understanding how clock gene system transcription–translation feedback loops function they are diminished PD. The article also discusses role genes regulation rhythms, well impact dysregulation on mitochondrial function, oxidative stress, neuroinflammation, including microbiota-gut-brain axis, which have all been proposed crucial mechanisms pathophysiology Finally, highlights potential therapeutic strategies targeting rhythm for treatment

Язык: Английский

Процитировано

3
Effectiveness of music-based interventions for cognitive rehabilitation in Parkinson’s disease: a systematic review of randomized controlled clinical trials DOI Creative Commons
Leonardo Francisco Citon, Amer Cavalheiro Hamdan

Psicologia Reflexão e Crítica, Год журнала: 2023, Номер 36(1)

Опубликована: Авг. 10, 2023

Abstract Background Music-based interventions are promising for cognitive rehabilitation in Parkinson’s disease; however, systematic reviews covering the topic scarce. Objective To analyze effectiveness of music-based PD. Method Systematic review study based on PRISMA criteria. The descriptors disease, idiopathic interventions, music therapy, training, auditory stimulation, music, rhythm, rhythmic, cognition, and were used. Five databases searched PubMed/MEDLINE, PsycInfo, Scopus, Web Science, Cochrane May 2022. Only randomized controlled trials with no limit publication date or language included. Risk bias was assessed following Collaboration criteria development intervention reviews. Results Nine hundred nineteen articles found by descriptors; 266 excluded being repeated; 650 not meeting inclusion remaining three included analyzed. consisted practices emphasis rhythm conducted groups. Risks important biases observed, such as lack blinding allocation participants assessment outcomes, well incomplete data some outcomes. Conclusion Overall, results showed evidence efficacy outcomes

Язык: Английский

Процитировано

2